Is Athira Pharma (ATHA) Stock Outpacing Its Medical Peers This Year?

Group 1 - Athira Pharma, Inc. (ATHA) has a year-to-date return of 29.6%, outperforming the Medical sector's average return of 5.3% [2][3] - The Zacks Consensus Estimate for ATHA's full-year earnings has increased by 10.3% over the past 90 days, indicating improved analyst sentiment and a stronger earnings outlook [2] - Athira Pharma, Inc. is ranked 2 (Buy) in the Zacks Rank, which highlights stocks with characteristics to outperform the market in the near term [1] Group 2 - Athira Pharma, Inc. is part of the Medical - Biomedical and Genetics industry, which has seen a decline of about 2.5% year-to-date, indicating that ATHA is performing better than its peers in this group [3] - HCA Healthcare (HCA), another outperforming stock in the Medical sector, has returned 30.4% year-to-date and has a consensus EPS estimate increase of 7.9% over the past three months [2][3] - The Medical - Hospital industry, which includes HCA Healthcare, has a year-to-date return of +31.7%, ranking 3 in the Zacks Industry Rank [3]